Pharma speaker programs are dying.
Not loudly. Nobody is holding a press conference. No company is announcing it. The line items will still appear in compliance reports for another two or three years. Some brand teams will still build launch plans around them. But the underlying model has already broken, and the data showing the collapse is sitting in plain sight across enforcement actions, Open Payments disclosures, and HCP preference surveys.
This is the structural shift pharma's commercial operating model has been quietly trying to manage for half a decade. It is now visible to anyone who looks. And it is reshaping how HCP engagement actually happens.
The Enforcement Wall
Start with what the Department of Justice has been doing.
In 2020, the Office of Inspector General issued a special fraud alert specifically warning about speaker programs. That alert told the industry, in plain language, that the entire category was now a permanent enforcement target.
The actions that followed have not been small.
In July 2020, Novartis paid six hundred and seventy-eight million dollars to resolve False Claims Act and Anti-Kickback Statute allegations that it had run sham speaker programs from 2002 through 2011, using cash payments, exorbitant speaker fees, and expensive dinners to induce prescribing of its cardiovascular and diabetes drugs. As part of the settlement, Novartis accepted a corporate integrity agreement that committed the company to paying external physicians "only in limited circumstances" and to no longer using restaurants as venues for any educational program.
That single corporate integrity agreement reset the operating norm for an entire category.
In January 2025, Pfizer paid fifty-nine point seven million dollars on behalf of its Biohaven subsidiary to resolve allegations that Biohaven had used speaker payouts and high-end restaurant meals to induce Nurtec prescribing.
In April 2025, Gilead Sciences paid two hundred and two million dollars to resolve allegations that it used speaker programs to induce HCPs to prescribe its HIV drugs.
In May 2025, Assertio Therapeutics paid three point six million dollars to resolve allegations centered on its use of speaker programs to induce prescribing of its fentanyl product Lazanda.
This is not a quiet enforcement cycle. This is a Department of Justice that has decided speaker programs are a structural risk surface, and that the standard of evidence is now whatever was happening at Novartis through 2011. Every active speaker program in 2026 is being evaluated against that bar by internal compliance, by external counsel, and increasingly by federal prosecutors.
The Spend Wall
The financial picture is just as clear.
ProPublica's Dollars for Docs analysis documented the first wave of speaker program contraction the moment full Open Payments transparency came into view. Eli Lilly's speaker spend dropped fifty-five percent in a single year, from forty-seven point nine million dollars in 2011 to twenty-one point six million in 2012. Pfizer's speaker spend fell sixty-two percent over the same period, from nearly twenty-two million dollars to eight point three million. Novartis cut speaker spend by forty percent in the same window.
From 2014 to 2018, total pharma and medtech spending on doctors for speaking, consulting, meals, travel, and gifts hovered at two point one to two point two billion dollars annually. That number has been compressing further every year since, driven by the enforcement environment, by COVID-era forced experimentation with remote formats, and by the gradual realization across commercial leadership that the speaker program return on investment is no longer easy to defend.
The fact that pharma is no longer publicly disclosing aggregate speaker spend the way ProPublica forced it to do a decade ago is itself part of the story. The data has gotten harder to track because the spend has gotten harder to justify internally.
The HCP Wall
Even if the enforcement environment were friendlier and the budgets were unconstrained, the model would still be breaking because HCPs no longer want it.
A Boston Consulting Group survey found that ninety-one percent of HCPs prefer remote speaker programs as a promotional channel. Eighty-seven percent of HCPs prefer a mix of remote engagements over in-person-only formats. The same body of research consistently reports that physicians want on-demand content that fits their schedules, not scheduled dinners that take a weeknight evening.
The same physicians who used to be the target audience for a Tuesday-night speaker program at a steakhouse are now consuming clinical updates through podcasts, peer-to-peer digital platforms, asynchronous video, and physician-led WhatsApp and Doximity discussions. Many of them are themselves the digital opinion leaders that pharma's competitors are already engaging through completely different channels.
When the customer has moved, the channel is by definition obsolete. It does not matter how skilled the rep was at filling a room. The room has moved.
What's Replacing It
The replacement engagement architecture is not a single channel. It is a system.
It includes virtual symposia and webinars that run on time, that can be rewatched, that produce structured engagement analytics. It includes peer-to-peer digital programs where HCPs talk to other HCPs through closed networks with light pharma touch. It includes short-form video, asynchronous case discussions, and AI-personalized content that meets each HCP at their own clinical interest level and schedule. It includes micro-learning modules, conference content syndication, and podcast formats that compete with the medical journals for share of attention.
It also includes a much smaller, much more selective, and much more carefully governed in-person program category. The companies still running in-person programs are running fewer of them, at lower cost per program, with stricter speaker selection, with no restaurants as venues, with documented educational content, and with audit trails that can survive a federal subpoena.
The speaker program has not disappeared. It has been demoted from a primary engagement channel to a secondary content event, embedded inside a broader digital and content engine.
What This Means for Pharma's Operating Model
Three implications follow.
First, the brand teams still building commercial plans that depend on speaker program reach are building plans on top of a collapsing channel. The reach math no longer works. The HCP attendance pool is older, smaller, and increasingly suspicious of the format. Continuing to allocate millions per brand to a channel that the customer has rejected is no longer a defensible budget decision.
Second, the medical and commercial divide that ran through traditional speaker programs is starting to dissolve. The replacement model is content-driven, peer-driven, and analytics-driven, which means medical affairs, marketing, and digital teams have to operate as a single function. The pharma companies that still treat medical content and commercial content as separate workflows will lose to the ones that operate them as a unified HCP engagement system.
Third, the AI question becomes unavoidable. Personalizing content at HCP level, generating compliant variants of medical material, tracking engagement signals across channels, and surfacing the right next-best action to the field force at the right moment are all AI problems. The companies that solve them well will pull the digital opinion leaders into their orbit and engage the larger HCP universe at a fraction of the cost per touchpoint of the speaker program model. The companies that do not will watch their share of voice fall through the floor while their compliance department breathes a quiet sigh of relief.
The Quiet Part
This is the quiet part that pharma rarely says out loud.
The speaker program model was never really about education. It was about creating high-fidelity human contact moments with prescribers in a regulated environment where direct gifts and direct payments were prohibited. The food, the venue, and the modest stipend created a relationship surface where the rep, the speaker, the brand, and the audience were all aligned around prescribing behavior in a way that no other channel could replicate at the time.
That model worked because the alternatives did not exist. The alternatives now exist. They are cheaper, more compliant, better measured, more popular with HCPs, and structurally easier to scale.
The speaker program is not being killed by the DOJ. It is being killed by every more attractive channel that has been built in the last decade. The DOJ enforcement is what makes the death visible. The HCP preference shift is what makes the death inevitable.
The Implication
Speaker programs are not going to be announced as discontinued. They are going to be quietly defunded, structurally limited, and gradually replaced by an engagement architecture that no individual decision-maker will ever sign off on as "the new speaker program."
The pharma companies that are already running that replacement system at scale are pulling ahead in HCP share of voice while spending less and exposing themselves to less compliance risk. The pharma companies that are still building 2026 brand plans around speaker program reach numbers are managing a channel that their customers have already left.
The decline is structural. The replacement is already operational. The transition is happening with or without internal acknowledgment.
The smart move is to stop defending the model and start building the system that replaces it.
